Therapeutic effect of intra-articular injected 3'-sialyllactose on a minipig model of rheumatoid arthritis induced by collagen.
3′-Sialyllactose
Intra-articular injection
Minipig
Rheumatoid arthritis
Journal
Laboratory animal research
ISSN: 1738-6055
Titre abrégé: Lab Anim Res
Pays: England
ID NLM: 101560684
Informations de publication
Date de publication:
22 Mar 2022
22 Mar 2022
Historique:
received:
12
10
2021
accepted:
16
03
2022
entrez:
22
3
2022
pubmed:
23
3
2022
medline:
23
3
2022
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is a chronic inflammatory disease of joint, but there is no known cure. 3'-sialyllactose (3'-SL) is an oligosaccharide that is abundant in breast milk of mammals, and has anti-inflammatory properties. However, the efficacy of 3'-SL on RA remains unclear. The objective of the present study was to evaluate the therapeutic effect of 3'-SL after it was directly injected into the knee joint cavity of a RA minipig model. Minipig RA model was induced by intra-articular injection of bovine type II collagen emulsified with complete or incomplete Freund's adjuvant into left knee joint. In clinical assessment, lameness and swelling of the hindlimb and increased knee joint width were observed in all animals. After the onset of arthritis, 3'-SL (0, 2, 10, and 50 mg/kg) was directly administered to the left knee joint cavity once a week for 4 weeks. Compared to the vehicle control group, no significant difference in macroscopic observation of the synovial pathology or the expression of inflammation-related genes (IL-1β, TNF-α, and COX2) in the synovial membrane of the knee joint was found. In microscopic observation, cell cloning of the articular cartilage was significantly reduced in proportion to the concentration of 3'-SL administered. Our results suggest that intra-articular injected 3'-SL had a therapeutic effect on collagen-induced arthritis at the cellular level with potential as a medication for RA.
Sections du résumé
BACKGROUND
BACKGROUND
Rheumatoid arthritis (RA) is a chronic inflammatory disease of joint, but there is no known cure. 3'-sialyllactose (3'-SL) is an oligosaccharide that is abundant in breast milk of mammals, and has anti-inflammatory properties. However, the efficacy of 3'-SL on RA remains unclear. The objective of the present study was to evaluate the therapeutic effect of 3'-SL after it was directly injected into the knee joint cavity of a RA minipig model.
RESULTS
RESULTS
Minipig RA model was induced by intra-articular injection of bovine type II collagen emulsified with complete or incomplete Freund's adjuvant into left knee joint. In clinical assessment, lameness and swelling of the hindlimb and increased knee joint width were observed in all animals. After the onset of arthritis, 3'-SL (0, 2, 10, and 50 mg/kg) was directly administered to the left knee joint cavity once a week for 4 weeks. Compared to the vehicle control group, no significant difference in macroscopic observation of the synovial pathology or the expression of inflammation-related genes (IL-1β, TNF-α, and COX2) in the synovial membrane of the knee joint was found. In microscopic observation, cell cloning of the articular cartilage was significantly reduced in proportion to the concentration of 3'-SL administered.
CONCLUSIONS
CONCLUSIONS
Our results suggest that intra-articular injected 3'-SL had a therapeutic effect on collagen-induced arthritis at the cellular level with potential as a medication for RA.
Identifiants
pubmed: 35314005
doi: 10.1186/s42826-022-00119-2
pii: 10.1186/s42826-022-00119-2
pmc: PMC8939226
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Subventions
Organisme : Ministry of Trade, Industry and Energy
ID : P0004751
Informations de copyright
© 2022. The Author(s).
Références
Bioresour Technol. 2014 Aug;166:9-16
pubmed: 24880807
Nat Rev Immunol. 2007 Jun;7(6):429-42
pubmed: 17525752
Clin Rev Allergy Immunol. 2016 Aug;51(1):27-47
pubmed: 26634933
J Interferon Cytokine Res. 2011 Dec;31(12):917-26
pubmed: 21905879
Vet Pathol. 2015 Sep;52(5):842-50
pubmed: 26163303
Reprod Toxicol. 2018 Sep;80:35-43
pubmed: 29940329
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S66-79
pubmed: 20864024
J Pharmacol Sci. 2016 Sep;132(1):41-47
pubmed: 27156927
Sci Rep. 2015 Oct 01;5:14713
pubmed: 26424611
Cell Tissue Res. 2020 May;380(2):287-304
pubmed: 32356014
Ann Intern Med. 1993 Nov 1;119(9):867-73
pubmed: 8214997
Annu Rev Immunol. 2008;26:651-75
pubmed: 18173373
Arthritis Res Ther. 2013;15 Suppl 3:S2
pubmed: 24267197
Biol Proced Online. 2013 Jul 15;15:8
pubmed: 23855709
J Musculoskelet Neuronal Interact. 2001 Jun;1(4):377-85
pubmed: 15758488
Ann Nutr Metab. 2016;69 Suppl 2:42-51
pubmed: 28103609
Arthritis Rheum. 1996 Jan;39(1):115-24
pubmed: 8546720
Immunol Today. 1984 Jun;5(6):173-5
pubmed: 25289746
J Rheumatol Suppl. 2002 Sep;65:3-9
pubmed: 12236620
Ann Rheum Dis. 2003 Nov;62(11):1049-53
pubmed: 14583566
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S80-92
pubmed: 20864026
Annu Rev Med. 2002;53:35-57
pubmed: 11818462
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Springer Semin Immunopathol. 2003 Aug;25(1):3-18
pubmed: 12904888
Eur J Immunol. 2009 Aug;39(8):2040-4
pubmed: 19672892
Regul Toxicol Pharmacol. 2018 Apr;94:83-90
pubmed: 29407203
Br J Pharmacol. 2018 Dec;175(23):4295-4309
pubmed: 30152858
J Cell Mol Med. 2018 Jan;22(1):57-66
pubmed: 28782172